New mRNA therapy targets Virus-Linked cancers
NCT ID NCT07349836
Summary
This early-stage study is testing a new mRNA-based immunotherapy for cancers associated with the Epstein-Barr virus (EBV), such as certain lymphomas and nasopharyngeal cancer. The study will enroll 40 adults to see if the treatment is safe and if it helps control the disease, either by itself or when combined with another immunotherapy drug. The goal is to provide a new treatment option for patients with these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.